Dirk Pollet
Vorstandsvorsitzender bei Enzyre BV
Aktive Positionen von Dirk Pollet
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Enzyre BV
Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | Vorstandsvorsitzender | 30.04.2019 | - |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Dirk Pollet
Ehemalige bekannte Positionen von Dirk Pollet
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Multiplicom NV
Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Direktor/Vorstandsmitglied | 15.04.2011 | 01.03.2017 |
Vorstandsvorsitzender | 03.05.2011 | 01.03.2017 | |
CELLECTIS S.A. | Corporate Officer/Principal | 28.05.2010 | 01.06.2011 |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Corporate Officer/Principal | 01.09.2000 | 02.05.2008 |
Ausbildung von Dirk Pollet
University of Antwerp | Doctorate Degree |
Statistik
International
Belgien | 4 |
Niederlande | 3 |
Frankreich | 2 |
Operativ
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Technology Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Private Unternehmen | 4 |
---|---|
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Multiplicom NV
Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Health Technology |
Enzyre BV
Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | Technology Services |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | Commercial Services |
- Börse
- Insiders
- Dirk Pollet
- Erfahrung